University of Illinois at Chicago
Chicago, Illinois, 60612, United States
NCT Number: NCT03935958
The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients.
This study is active but is not currently recruiting participants.
18 year and older
All sexes
Interventional
Not applicable
Chicago, Illinois, 60612, United States
Kidney transplant recipients are at increased risk of death from cardiovascular disease (CVD). Inflammation, oxidative stress and vascular dysfunction (impaired endothelial function and increased large elastic artery stiffness), are highly prevalent in kidney transplant recipients and contribute to the high incidence of CVD in this patient population. The most common cause of kidney transplant failure is interstitial fibrosis and tubular atrophy (IFTA). The incidence of IFTA is as high as 50% of kidney transplants at 1 year after transplantation. The pathophysiology of IFTA is not well understood. Possible mechanisms include chronic rejection or injury, inflammation, and drug toxicity. Kidney transplant recipients suffer from high rates of cognitive decline for which the investigators lack effective therapies. Thus, therapeutic interventions targeting inflammation, oxidative stress, vascular dysfunction, and cognitive impairment are a priority.
Curcumin may have positive effects in terms of cardiovascular and nephroprotection because of its antibacterial, antiviral, anti-inflammatory and anti-oxidative effects. The aim of this study is to elucidate the role of curcumin as a nutritional strategy to reduce cardiovascular risk factors as well as inflammation and oxidative stress in kidney transplant recipients. The study aims to examine if curcumin will improve endothelial function by reducing markers of inflammation and oxidative stress. In addition, the study will evaluate the potential benefit of curcumin on cognitive function in kidney transplant recipients.
Curcumin is a natural polyphenol with anti-inflammatory and antioxidant characteristics. Preliminary data indicate that curcumin administration improves endothelial dysfunction by reducing oxidative stress and inflammation and may improve cognitive function.
The primary goal of this study is to investigate if curcumin is beneficial for kidney transplant recipients, a population with extensive baseline vascular dysfunction and cognitive impairment who have few treatment options. The possible mechanisms by which curcumin improves vascular function will be evaluated as well as whether curcumin improves cognitive function in these patients.
Objectives:
Methods:
Patients will be randomized 1:1 to receive either curcumin or placebo starting at the time of transplant or up to 2 weeks prior to transplant. Patients will be followed per standard of care for kidney transplant recipients. Additional blood (30mL) and urine samples will be drawn prior to transplant and at 3, 6 and 12 months post-transplant to be used for future analysis. There will be a total of 4 visits for this study. Additionally, two questionnaires will be distributed at each visit.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Patients will receive curcumin 2000 mg a day, for 12 months
Other names: Longvida
Patients will receive placebo capsule identical in appearance and taste to the supplement, for 12 months
Other names: Longvida
Time frame: 12 months
Change in GFR at 3, 6 and 12 months
Time frame: 12 months
Change in Neuro-QOL Item Bank v2.0 at 0, 3, 6, and 12 months
Time frame: 12 months
Difference in biopsy scores at 3 and 12 months
Time frame: 12 months
Global Pain Scale at 0, 3, 6, and 12 months
Time frame: 12 months
Markers of inflammation and oxidative stress at 0,3,6, & 12 months
University of Illinois at Chicago
Other
A Pilot 12 Month, Randomized, Controlled Trial of Curcumin in Kidney Transplant Recipients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01744067
Disorder Related to Renal Transplantation, Female Urogenital Diseases
Oslo, * Other, Norway
View Trial DetailsNCT02843867
Arterial Occlusive Diseases, Arteriosclerosis
Besançon, France
View Trial DetailsNCT06584773
Disorder Related to Renal Transplantation
São Paulo, Brazil
View Trial DetailsNCT00905957
Disorder Related to Renal Transplantation, Neurologic Manifestations
Liverpool, Merseyside, United Kingdom
View Trial Details